{"id":669806,"date":"2026-11-11T14:55:13","date_gmt":"2026-11-11T18:55:13","guid":{"rendered":"https:\/\/www.malayalamdailynews.com\/english\/669806\/"},"modified":"2026-11-11T14:55:13","modified_gmt":"2026-11-11T18:55:13","slug":"ozempic-wegovy-mounjaro-among-drugs-linked-to-possible-vision-loss-fda-issues-new-warning","status":"publish","type":"post","link":"https:\/\/www.malayalamdailynews.com\/english\/669806\/","title":{"rendered":"Ozempic, Wegovy, Mounjaro Among Drugs Linked to Possible Vision Loss; FDA Issues New Warning"},"content":{"rendered":"
\"Ozempic,<\/figure>\n

WASHINGTON, November 10, 2026 \u2014 The U.S. Food and Drug Administration (FDA) has issued a warning that users of medications widely used worldwide to control diabetes and reduce excess weight \u2014 including Ozempic, Wegovy, Mounjaro, and Zepbound \u2014 may face the risk of rare eye disease and permanent vision loss. The official safety communication, released on November 9, mandates that labels of GLP-1 class drugs must include a new warning. This action followed an evaluation of recent studies and clinical trials regarding these drugs\u2019 safety.<\/p>\n

The condition associated with these drugs is known as Non-Arteritic Anterior Ischemic Optic Neuropathy (NAION). It occurs when blood flow to the front part of the optic nerve \u2014 which transmits visual signals from the eye to the brain \u2014 is reduced. A sudden, painless vision loss in one eye is the primary symptom, and in some cases, the vision loss can be permanent.<\/p>\n

The FDA reviewed data from 126 clinical trials that included information on 1,34,253 individuals. Among GLP-1 drug users, 6.4 NAION cases per 100,000 person-years were identified, compared to 3.8 cases per 100,000 person-years in the comparison groups. These findings suggest a possible increase in risk, although the condition remains very rare according to these figures.<\/p>\n

Previously, in June 2025, the European Medicines Agency (EMA) confirmed that NAION could be a very rare side effect in people using semaglutide, the main ingredient in Ozempic, Wegovy, and Rybelsus, estimating an incidence of up to one in 10,000 users. However, this estimate does not necessarily apply equally to all GLP-1 medications.<\/p>\n

The FDA advises that if symptoms such as sudden blurred vision, partial loss of vision in one eye, the appearance of dark spots, or differences in color recognition occur, urgent medical attention should be sought. Other risk factors for NAION include diabetes, high blood pressure, sleep apnea, kidney disease, and smoking. Thus, the risk associated with medication use needs to be assessed in the context of the patient\u2019s existing health conditions.<\/p>\n

Health experts stress that the use of Ozempic, Wegovy, Mounjaro, and similar drugs is not banned, and patients should not stop their medications without consulting their doctors. Any sudden changes in vision require prompt examination by an eye specialist who will determine whether treatment should continue.<\/p>\n

The FDA warning is based on evidence suggesting a possible link between these drugs and NAION. It has not been established that vision loss occurs in all patients or that all drugs directly cause the condition. Given that millions worldwide use these medications for diabetes and obesity management, the warning about this rare but serious side effect holds significant public health importance.<\/p>\n

Primary source: FDA Official Drug Safety Communication, November 9, 2026.<\/p>\n

n<\/p>\n

Original Malayalam report: Malayalam Daily News<\/a><\/small><\/p>\n","protected":false},"excerpt":{"rendered":"

WASHINGTON, November 10, 2026 \u2014 The U.S. Food and Drug Administration (FDA) has issued a warning that users of medications widely used worldwide to control diabetes and reduce excess weight \u2014 including Ozempic, Wegovy, Mounjaro, and Zepbound \u2014 may face the risk of rare eye disease and permanent vision loss. The official safety communication, released on November 9, mandates that labels of GLP-1 class drugs must include a new warning. This action followed an evaluation of recent studies and clinical trials regarding these drugs\u2019 safety. The condition associated with these…<\/p>\n","protected":false},"author":0,"featured_media":669807,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[6,582,47748],"tags":[],"class_list":["post-669806","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-6","category-english","category-news"],"_links":{"self":[{"href":"https:\/\/www.malayalamdailynews.com\/english\/wp-json\/wp\/v2\/posts\/669806","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.malayalamdailynews.com\/english\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.malayalamdailynews.com\/english\/wp-json\/wp\/v2\/types\/post"}],"replies":[{"embeddable":true,"href":"https:\/\/www.malayalamdailynews.com\/english\/wp-json\/wp\/v2\/comments?post=669806"}],"version-history":[{"count":0,"href":"https:\/\/www.malayalamdailynews.com\/english\/wp-json\/wp\/v2\/posts\/669806\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.malayalamdailynews.com\/english\/wp-json\/wp\/v2\/media\/669807"}],"wp:attachment":[{"href":"https:\/\/www.malayalamdailynews.com\/english\/wp-json\/wp\/v2\/media?parent=669806"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.malayalamdailynews.com\/english\/wp-json\/wp\/v2\/categories?post=669806"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.malayalamdailynews.com\/english\/wp-json\/wp\/v2\/tags?post=669806"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}